11,414 Shares in Mesoblast Limited $MESO Bought by Ballentine Partners LLC

Ballentine Partners LLC purchased a new stake in Mesoblast Limited (NASDAQ:MESO) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,414 shares of the company’s stock, valued at approximately $124,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in MESO. BNP Paribas Financial Markets grew its position in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock valued at $51,000 after purchasing an additional 2,597 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Mesoblast by 1,174.2% in the first quarter. GAMMA Investing LLC now owns 85,513 shares of the company’s stock valued at $1,067,000 after purchasing an additional 78,802 shares during the last quarter. Summit X LLC grew its position in shares of Mesoblast by 36.0% in the first quarter. Summit X LLC now owns 198,163 shares of the company’s stock valued at $2,473,000 after purchasing an additional 52,508 shares during the last quarter. Choreo LLC acquired a new stake in shares of Mesoblast in the first quarter valued at about $128,000. Finally, Advisors Preferred LLC grew its position in shares of Mesoblast by 224.9% in the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company’s stock valued at $54,000 after purchasing an additional 3,169 shares during the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Stock Up 0.6%

MESO stock opened at $16.11 on Wednesday. Mesoblast Limited has a 1-year low of $7.09 and a 1-year high of $22.00. The business’s 50 day moving average is $15.43 and its 200-day moving average is $12.90. The company has a current ratio of 1.99, a quick ratio of 1.77 and a debt-to-equity ratio of 0.11.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MESO. Jefferies Financial Group downgraded Mesoblast from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Canaccord Genuity Group raised Mesoblast to a “strong-buy” rating in a research report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Mesoblast has an average rating of “Buy” and an average target price of $24.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.